Stryker, Boston Scientific tie-up could create ‘higher growth Medtronic’

Analysts are eagerly digging into the news that Stryker (NYSE:SYK) put in a takeover bid with Boston Scientific (NYSE:BSX), though many were surprised by the news and are unsure of the obvious strategic value of the acquisition.

News of the deal, which both companies have officially responded to with statemens of “no comment,” emerged yesterday at the Wall Street Journal.

The merger could create a “higher growth Medtronic,” according to Evercore’s Vijay Kumar, adding approximately 2% to Stryker’s expected 2019 earnings per share and up to 6% by next year, SeekingAlpha reported.

Get the full story on our sister site MassDevice.

Inside Hologic's evolving definition of women's healthcare Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business. At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it! REGISTER NOW Use code WOMENSHEALTH to save an additional 10%.